EXCLUSIVE LICENSE AND COMMERCIALIZATION AGREEMENTExclusive License and Commercialization Agreement • May 3rd, 2021 • Therapeutics Acquisition Corp. • Pharmaceutical preparations • Ontario
This Exclusive License and Commercialization Agreement (this “Agreement”), dated as of 16 December 2020 (“Effective Date”), is made by and between POINT Biopharma Inc., having an address 4850 West 78th Street, Indianapolis, Indiana 46268, United States (“POINT”); Canadian Molecular Probe Consortium having a business office at C/O CPDC, Nuclear Research Building - A316, 1280 Main Street West, Hamilton, Ontario, Canada, L8S 4K1 (“CanProbe”); the Centre for Probe Development and Commercialization having a business office at Nuclear Research Building - A316, 1280 Main Street West, Hamilton, Ontario, Canada, L8S 4K1 (“CPDC”); and the University Health Network having a business office at 101 College Street, Suite 150, Heritage Building, MaRS Centre, Toronto, Ontario M5G 1L7 Canada (“UHN”). CanProbe, CPDC and UHN are collectively referred to herein as “Licensor”. Each of POINT, CanProbe, CPDC and UHN may be referred to herein as a “Party” or together as “Parties”.
EXCLUSIVE LICENSE AND COMMERCIALIZATION AGREEMENTExclusive License and Commercialization Agreement • September 11th, 2013 • Pluristem Therapeutics Inc • Biological products, (no disgnostic substances) • New York
Pluristem Ltd. an Israel corporation, having its principal place of business at MATAM Advanced Technology Park, Building No. 5, Haifa 31905 Israel (“Pluristem”);and
FIRST AMENDMENT TO EXCLUSIVE LICENSE AND COMMERCIALIZATION AGREEMENTExclusive License and Commercialization Agreement • March 27th, 2023 • POINT Biopharma Global Inc. • Pharmaceutical preparations
This First Amendment to the Exclusive License and Commercialization Agreement (this “Amendment”) is dated 04 November 2022 but is deemed to take effect as of December 16, 2020 (“Effective Date”) and is entered into by and between: Point Biopharma Inc., a Delaware corporation with a principal place of business at 511 South Orange Avenue, No. 2093, Newark, New Jersey, 07103, USA (“POINT”); Canadian Molecular Probe Consortium having a place of business at c/o McMaster University, Nuclear Research Building A316, 1280 Main Street West, Hamilton, Ontario, Canada, L8S 4K1, (“CanProbe”); Centre for Probe Development and Commercialization having a place of business at McMaster University, Nuclear Research Building A316, 1280 Main Street West, Hamilton, Ontario, Canada, L8S 4K1, (“CPDC”); and The University Health Network having a business office at 101 College Street, Suite 150, Heritage Building, Ma RS Centre, Toronto, Ontario M5G 1L7 Canada (“UHN”).
Certain information in this exhibit has been omitted because it is permitted to be omitted by applicable regulatory guidance. Amendment to and Waiver under Exclusive License and Commercialization AgreementExclusive License and Commercialization Agreement • March 15th, 2024 • Coherus BioSciences, Inc. • Biological products, (no disgnostic substances)
This Amendment to and Waiver under the Exclusive License and Commercialization Agreement (this “Amendment”) is made and entered into as of October 25, 2023, by and between Shanghai Junshi Biosciences Co., Ltd. (“Junshi”) and Coherus BioSciences, Inc. (“Coherus”). Each of Junshi and Coherus is sometimes referred to herein, individually, as a “Party” and, collectively as the “Parties.”
EXCLUSIVE LICENSE AND COMMERCIALIZATION AGREEMENT BY AND BETWEEN COHERUS BIOSCIENCES, INC. AND SHANGHAI JUNSHI BIOSCIENCES CO., LTD. DATED AS OF FEBRUARY 1, 2021Exclusive License and Commercialization Agreement • May 6th, 2021 • Coherus BioSciences, Inc. • Biological products, (no disgnostic substances) • New York
THIS EXCLUSIVE LICENSE AND COMMERCIALIZATION AGREEMENT (this “Agreement”) is entered into as of 1 February 2021 (the “Execution Date”) by and among Shanghai Junshi Biosciences Co., Ltd., a corporation organized and existing under the laws of the People’s Republic of China, with a registered address at Level 13, Building 2, Nos. 36 and 58, Hai Qu Road, China (Shanghai) Pilot Free Trade Zone, China 201203 (“Junshi”), and Coherus BioSciences, Inc., a Delaware corporation having its principal place of business at 333 Twin Dolphin Drive, Suite 600 Redwood City, CA 94065 (“Coherus”). Junshi and Coherus are referred to herein individually as a “Party” and collectively as the “Parties.”
Certain information in this exhibit has been omitted because it is permitted to be omitted by applicable regulatory guidance. Amendment No. 2 to Exclusive License and Commercialization AgreementExclusive License and Commercialization Agreement • May 9th, 2024 • Coherus BioSciences, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 2 to the Exclusive License and Commercialization Agreement, as amended (this “Amendment No. 2”), is made and entered into as of March 13, 2024, by and between Shanghai Junshi Biosciences Co., Ltd. (“Junshi”) and Coherus BioSciences, Inc. (“Coherus”). Each of Junshi and Coherus is sometimes referred to herein, individually, as a “Party” and, collectively as the “Parties.”
Jaguar Health Enters Exclusive Crofelemer License and Commercialization Agreement with SynWorld Technologies for Canalevia for Treatment of Diarrhea in Dogs in China License fees of $5.0 million, and up to $5.0 million in unregistered equity infusion,...Exclusive License and Commercialization Agreement • June 29th, 2022 • Jaguar Health, Inc. • Pharmaceutical preparations
SAN FRANCISCO, CA / June 29, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that the company has entered an exclusive license and services agreement with Ontario, Canada-based SynWorld Technologies Corporation (SynWorld) for the treatment of diarrhea in dogs in the China market with Jaguar’s Canalevia® (crofelemer delayed-release tablets) prescription drug product.
